First-pass extracted concept

non-haematopoietic Epo analogues

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

An overview of non-haematopoietic Epo analogues, which are a reliable alternative to the classic EpoR agonists and may prevent undesired side effects, is also provided.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2013International Journal of CardiologyDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1alternative positioningsupports2013Source 1DOI PubMed

Non-haematopoietic Epo analogues are presented as reliable alternatives to classic EpoR agonists that may prevent undesired side effects.

Claim 2scope summarysupports2013Source 1DOI PubMed

Erythropoietin has pleiotropic actions beyond erythroid progenitor cells because Epo receptor is identified in multiple non-haematopoietic cells and tissues, including myocardium.

Claim 3therapeutic positioningsupports2013Source 1DOI PubMed

Recombinant human erythropoietin and its analogues are reviewed as candidate interventions for limiting infarct size and left ventricular remodelling after acute myocardial infarction in humans.